Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
Citations Over TimeTop 10% of 2019 papers
Abstract
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years, remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies. Despite these findings, the current standard of care for DLBCL patients is still R-CHOP, and optimization of frontline therapy remains an important goal. In this review, we summarize recent updates on the evolution of frontline therapies for DLBCL.
Related Papers
- → UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma(2015)58 cited
- → P059 Long-term results of CHOP/CHOP like chemotherapy ± rituximab in patients with diffuse large B-cell lymphoma (DLBCL)(2007)
- → Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP(2023)
- → Supplementary Figure Legends 1-2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP(2023)
- → ABCL-504 Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in the United States(2023)